ReviewCephalalgia : an international journal of headache2009
Neurological mechanisms of migraine: potential of the gap-junction modulator tonabersat in prevention of migraine.
Review in Cephalalgia : an international journal of headache, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Tonabersat Blocks Gap Junctions and Alleviates Thermal Pain Behavior in Mice.International journal of molecular sciences · 2026Article
- Calcitonin gene-related peptide differentially modulates intracellular calcium levels in response to depolarizing stimuli in trigeminal ganglion neurons and glial cells.Neuroscience · 2025Article
- Tonabersat enhances temozolomide-mediated cytotoxicity in glioblastoma by disrupting intercellular connectivity through connexin 43 inhibition.Molecular oncology · 2025Article
- A cross-sectional, multicenter survey of the prevalence and influencing factors for migraine in epilepsy.Epilepsia open · 2024Article
- Cx43 hemichannels contribute to astrocyte-mediated toxicity in sporadic and familial ALS.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- The Vasodilatory Response to CGRP of the Anterior and Posterior Cerebral Circulation in Migraine.Frontiers in neurology · 2022Article
- Do anti-CGRP drugs have a role in migraine aura therapy?Journal of neurology · 2021Article
- Emerging importance of satellite glia in nervous system function and dysfunction.Nature reviews. Neuroscience · 2020Review
- Inhibition of gap junctional intercellular communication by an anti-migraine agent, flunarizine.PloS one · 2019Article
- Understanding Spreading Depression from Headache to Sudden Unexpected Death.Frontiers in neurology · 2018Review
- Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Article
- Typical aura without headache: a case report and review of the literature.Journal of medical case reports · 2015Review
- Involvement of gap junction channels in the pathophysiology of migraine with aura.Frontiers in physiology · 2014Review
- Gabapentin inhibits central sensitization during migraine.Neural regeneration research · 2013Article
- Why do migraines often decrease as we age?Current pain and headache reports · 2013Review
- Cortical spreading depression as a target for anti-migraine agents.The journal of headache and pain · 2013Review
- Dietary grape seed polyphenols repress neuron and glia activation in trigeminal ganglion and trigeminal nucleus caudalis.Molecular pain · 2010Article
- Cortical spreading depression: origins and paths as inferred from the sequence of events during migraine aura.Functional neurologyArticle
- Anchored PKA as a gatekeeper for gap junctions.Communicative & integrative biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Migraine is a neurovascular disorder characterized by recurrent episodic headaches, and is caused by abnormal processing of sensory information due to peripheral and/or central sensitization. The exact pathophysiological mechanism underlying migraine is not fully understood; however, cortical spreading depression (CSD) is thought to provide the basis for migraine aura and may serve as a trigger of migraine pain. CSD depends on neuronal-glial cell communication, which is mediated by intercellular transfer of messengers through connexin-containing gap junctions, as well as messengers released into the extracellular space by non-junctional connexin-containing hemichannels. These processes are believed to be important in peripheral sensitization within the trigeminal ganglion and to lead to central sensitization. The novel benzopyran compound tonabersat binds selectively to a unique site in the brain. In preclinical studies, tonabersat markedly reduced CSD and CSD-associated events and inhibited gap-junction communication between neurons and satellite glial cells in the trigeminal ganglion. Together, these findings suggest that tonabersat should have clinical application in preventing migraine attacks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.